secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-03-17T23:59:59+00:00
Accession:  0001654954-25-002886
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata reports FY2024 cash burn; Phase 3 STAR-1 topline expected by end of March 2025
--------------------------------------------------------------------------------

- Cash and cash equivalents $3.2M as of Dec. 31, 2024, down from $7.4M; expects funding into Q3 2025 after $2.55M Jan. 2025 PIPE.
- R&D expense $8.2M in 2024 vs $4.1M in 2023, driven by $4.9M increase in Phase 3 STAR-1 clinical trial costs.
- Topline results from XYNGARI Phase 3 STAR-1 acne trial expected by end of March 2025.
- Entered Clinical Trial Collaboration Agreement with Revance (Crown Laboratories) to study DMT410 with DAXXIFY for hyperhidrosis.
- G&A expense $4.3M in 2024 vs $4.0M in 2023, primarily due to increased audit fees from auditor change.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495425002886/0001654954-25-002886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495425002886/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-002886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer